Media Statement from Cancer Institute and Hospital, Tianjin Medical University

TIANJIN, China, Sept. 21, 2015 /PRNewswire/ -- Recently Mr. Zhenguo SONG published a paper, The Clinical Significance and Regulation Mechanism of Hypoxia-Inducible Factor-1 and Mir-191 Expression in Pancreatic Cancer. Tumour Biol.2014 Nov; 35(11):11319-28. It is claimed to be the accomplishment of three authors, Professor Jihui HAO, Associate Professor He REN and Mr. Zhenguo SONG.

The following statement on this paper is made by Cancer Institute and Hospital, Tianjin Medical University:

Professor Jihui HAO and Associate Professor He REN are staff of Cancer Institute and Hospital, Tianjin Medical University. The Paper was submitted by co-author Mr. Zhenguo SONG without prior permission from the other co-authors and published by Tumor Biology. A request from Professor HAO and Associate Professor REN to retract the Paper from Tumor Biology was declined by the magazine. Professor HAO and Professor REN hereby declare that they have no intention of publishing this ongoing paper and take no responsibibility for all the data and views in the paper.

About The Tianjin Medical University Cancer Institute and Hospital

The Tianjin Medical University Cancer Institute and Hospital has a rich history going back more than a century ago and is the birthplace of Oncology in China. The hospital was originally established in 1861 as the London Christian Church Hospital. The hospital was renamed as "Tianjin Municipal People's Hospital" in 1950 after the founding of the People's Republic of China. In 1952, the first tumor ward in China was established in our hospital by the pioneering oncologist Prof. Jin Xian-Zhai, who returned to China after his training in the United States. Initially, the hospital was specialized in both orthopedics and oncology. In 1972, the orthopedics component was separated to become a specialized orthopedics hospital thus the remaining hospital became a specialized cancer hospital with 341 beds. In 1977, the Institute of Cancer Research was established with 8 departments. In 1987, the hospital was moved to the present site and was renamed as "Tianjin Cancer Institute and Hospital". In 1996, the hospital became affiliated with the Tianjin Medical University and officially named as Tianjin Medical University Cancer Institute and Hospital (TMUCIH). With more than a century of history, TMUCIH has developed into a large highly specialized cancer facility with integrated patient care, education/training, research and prevention activities. It is one of the top cancer facilities in China and provide cancer treatment not only to people in Tianjin and northern part of China, but also other regions of China as well as foreign patients. It has the largest breast cancer center nationwide. The "Tianjin Breast Cancer Center for Treatment and Prevention" was built in 1999 and opened in 2004. TMUCIH was designated as a clinical trial center by the Chinese SFDA since 1998. Six medical oncology wards have been designated to the clinical research center. There have been more than 250 clinical trails completed and about 50 trials undergoing.

SOURCE Cancer Institute and Hospital, Tianjin Medical University